Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site

Cancer Research

Volumn 61, Issue 2, 2001, Pages 504-508

  Urasaki, Yoshimasa ^b   Laco, Gary ^d   Takebayashi, Yuji ^d   Bailly, Christian ^d   Kohlhagen, Glenda ^d   Pommier, Yves ^d  

^a TOHOKU UNIVERSITY   (Japan)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Institut de Recherche sur le Cancer de Lille   (France)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

6 FORMYLAMINO 12,13 DIHYDRO 1,11 DIHYDROXY 5H INDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 GLUCOSIDE; CAMPTOTHECIN; CARBAZOLE DERIVATIVE; DNA TOPOISOMERASE; INDOLE DERIVATIVE; J 109382; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING SITE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; CROSS RESISTANCE; DNA CLEAVAGE; DRUG MECHANISM; GENE MUTATION; HUMAN; HUMAN CELL; INTERCALATION COMPLEX; MAMMAL CELL; NONHUMAN; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BINDING SITES; CAMPTOTHECIN; CARBAZOLES; CELL SURVIVAL; DNA TOPOISOMERASES, TYPE I; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GLUCOSIDES; HUMANS; INTERCALATING AGENTS; MUTATION; STEREOISOMERISM; TUMOR CELLS, CULTURED;

EID: 0035863393     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5′-phosphorylated DNA double-strand breaks by replication runoff
2. Topoisomerase I inhibitors: Selectivity and cellular resistance
3. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme
4. Non-camptothecin topoisomerase I active compounds as potential anticancer agents
5. Topoisomerase 1 poisons and suppressors as anticancer drugs
6. Induction of topoisomerase 1-mediated DNA cleavage by a new indolocarbazole, ED-110
7. Novel antitumor indolocarbazole compound 6-N-fonnylamino-12,13-dihydro-1,11-dihydroxy-13-(β-D-glucopyranosyl)-5H- indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506): Induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity
8. Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase 1
9. In vivo anti-tumor activity of a novel indolocarbazole compound, J-107088, on murine and human tumors transplanted into mice
10. Synergic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 10864)
11. In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells
12. Induction of topoisomerase I cleavage complexes by 1-β-D-arabinofuranosylcytosine (ara-C) in vitro and in ara-C-treated cells
13. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin
14. Silencing and selective methylation of the normal topoisomerase I gene in camptothecin-resistant CEM/C2 human leukemia cells
15. Cloning of Chinese hamster DNA topoisomerase I cDNA and identification of a single point mutation responsible for camptothecin resistance
16. Overexpression of human DNA topoisomerase I in insect cells using a baculovirus vector
17. Isolation of intercalator-dependent protein-linked DNA strand cleavage activity from cell nuclei and identification as topoisomerase II
18. Topoisomerase 1 alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture
19. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin
20. Intercalation into DNA is not required for inhibition of topoisomerase I by indolocarbazole antitumor agents
21. Camptothecin and Taxol: Discovery to clinic-thirteenth Bruce F. Cain Memorial Award lecture
22. Camptothecins: From bench research to hospital wards
23. The camptothecins
24. The structural basis of camptothecin interactions with human serum albumin: Impact on drug stability
25. Crystal structure of human topoisomerase 1 in covalent and noncovalent complexes with DNA
26. A model for the mechanism of human topoisomerase 1
27. The camptothecin-resistant topoisomerase 1 mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase 1 inhibition by indolocarbazoles
28. Effect of local DNA sequence on topoisomerase 1 cleavage in the presence or absence of camptothecin
29. Molecular modeling studies of the DNA-topoisomerase 1 ternary cleavable complex with camptothecin
30. Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase 1-DNA cleavage sites
31. Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue
32. UCN-01: A potent abrogator of G2 checkpoint function in cancer cells with disrupted p53
33. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53
34. The staurosporine-like compound L-753,000 (NB-506) potentiates the neurotrophic effects of neurotrophin-3 by acting selectively at the TrkA receptor
35. Antitumor activities of a new indolocarbazole substance, NB-506, establishment of NB-506-resistant cell lines, SBC-3/NB
36. A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I